Scarica l'app Stockscreener
16.98
0.93%
-0.16
Dopo l'orario di chiusura:
16.98
Precedente Chiudi:
$17.14
Aprire:
$17.05
Volume 24 ore:
161.57K
Relative Volume:
0.88
Capitalizzazione di mercato:
$715.03M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+4.43%
1M Prestazione:
+1.01%
6M Prestazione:
+145.02%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$16.36
$17.33
Intervallo di 1 settimana:
$15.82
$18.29
Portata 52W:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Nome
Zenas Biopharma Inc
Settore
Industria
Telefono
857-271-2954
Indirizzo
852 WINTER STREET, SUITE 250, WALTHAM
Confronta ZBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
16.98 | 737.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-20 | Iniziato | Wedbush | Outperform |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-05 | Iniziato | Rodman & Renshaw | Buy |
| 2024-10-08 | Iniziato | Citigroup | Buy |
| 2024-10-08 | Iniziato | Guggenheim | Buy |
| 2024-10-08 | Iniziato | Jefferies | Buy |
| 2024-10-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Zenas Biopharma Inc Borsa (ZBIO) Ultime notizie
Can Zenas BioPharma Inc. hit a new high this month2025 Market Sentiment & Risk Managed Trade Strategies - Newser
Is Zenas BioPharma Inc. trading at a discountJuly 2025 Institutional & Entry Point Confirmation Signals - khodrobank.com
Pattern recognition hints at Zenas BioPharma Inc. upside2025 Retail Activity & Weekly High Momentum Picks - Newser
What MACD and RSI say about Zenas BioPharma Inc.Market Risk Analysis & Long-Term Safe Investment Ideas - Newser
Strategic Funding Boost: Zenas BioPharma’s Partnership with Royalty Pharma Enhances Obexelimab’s Commercial Potential - TipRanks
Trend analysis for Zenas BioPharma Inc. this weekJuly 2025 Final Week & Growth-Oriented Investment Plans - Newser
What institutional flow reveals about Zenas BioPharma Inc.2025 Earnings Surprises & Fast Momentum Entry Tips - Newser
What machine learning models say about Zenas BioPharma Inc.Weekly Investment Report & Fast Entry Momentum Alerts - Newser
How to integrate Zenas BioPharma Inc. into portfolio analysis toolsMarket Trend Review & Reliable Entry Point Alerts - Newser
Real time breakdown of Zenas BioPharma Inc. stock performanceGap Up & Free Reliable Trade Execution Plans - Newser
Is Zenas BioPharma Inc. meeting your algorithmic filter criteriaQuarterly Portfolio Summary & Weekly Setup with High ROI Potential - Newser
Zenas BioPharma secures $300M funding from Royalty Pharma for obexelimab royalties. - AInvest
Published on: 2025-09-03 01:34:16 - Newser
How moving averages guide Zenas BioPharma Inc. tradingJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - Newser
Using data filters to optimize entry into Zenas BioPharma Inc.Portfolio Value Summary & Daily Volume Surge Signals - Newser
What’s the RSI of Zenas BioPharma Inc. stockWeekly Market Report & Consistent Income Trade Recommendations - khodrobank.com
Wuxi XDC offers up to 22.3 million shares at HK$58.85 each - AInvest
Tick level data insight on Zenas BioPharma Inc. volatility2025 Momentum Check & Expert Curated Trade Ideas - Newser
Sasol Limited shares rise 2.89% intraday after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Servier pays $200M upfront to Ideaya; Zymeworks ends work on T cell engager - Endpoints News
Lead Plaintiff Appointed in Zenas BioPharma Class Action — Here’s How You Can Recover Your Losses - TradingView
Beone Medicines Ltd. shares rise 8.81% premarket after Royalty Pharma and Zenas BioPharma enter into a $300 million funding agreement. - AInvest
Zenas Biopharma and Royalty Pharma enter into obexelimab funding agreement for up to $300 million - MarketScreener
Zenas BioPharma, Royalty Pharma Enter $300 Million Funding Agreement for Obexelimab - MarketScreener
Zenas BioPharma Secures Up To $300 Mln Funding From Royalty Pharma For Obexelimab - Nasdaq
Bolt Projects Holdings, Inc. shares rise 1.54% premarket after Royalty Pharma and Zenas BioPharma announced a $300 million funding deal for obexelimab. - AInvest
Zenas BioPharma Secures $300M Funding for Obexelimab - TipRanks
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million - citybiz
Zenas BioPharma, Royalty Pharma Partner for $300mln Obexelimab Funding Agreement - AInvest
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - GlobeNewswire
Royalty Pharma provides up to $300 million to Zenas BioPharma for obexelimab - StreetInsider
Zenas BioPharma Secures Up to $300 Million Funding for Obexelimab Development and Potential IgG4-RD Launch - AInvest
Zenas BioPharma, Inc. and Royalty Pharma Enter into Obexelimab Funding Agreement for Up to $300 Million - MarketScreener
Quantitative breakdown of Zenas BioPharma Inc. recent moveEarnings Risk Report & Real-Time Volume Spike Alerts - Newser
Does Zenas BioPharma Inc. show high probability of reboundWeekly Risk Report & AI Forecast Swing Trade Picks - Newser
Technical signs of recovery in Zenas BioPharma Inc.Long Setup & Real-Time Stock Entry Alerts - Newser
Will Zenas BioPharma Inc. outperform its industry peersWeekly Profit Analysis & Smart Investment Allocation Tips - khodrobank.com
Does Zenas BioPharma Inc. stock benefit from AI growthTrade Risk Report & Precise Buy Zone Tips - khodrobank.com
Is Zenas BioPharma Inc. stock overvalued or fairly pricedWeekly Stock Summary & Reliable Breakout Stock Forecasts - khodrobank.com
Can Zenas BioPharma Inc. reach all time highs this year2025 AllTime Highs & Safe Entry Trade Signal Reports - khodrobank.com
Can Zenas BioPharma Inc. deliver consistent dividendsEarnings Trend Report & Verified Entry Point Detection - khodrobank.com
Chart based exit strategy for Zenas BioPharma Inc.Portfolio Performance Summary & Capital Protection Trading Alerts - Newser
Applying Elliott Wave Theory to Zenas BioPharma Inc.Trade Volume Summary & Long-Term Growth Portfolio Plans - Newser
Using data models to predict Zenas BioPharma Inc. stock movementMarket Weekly Review & Weekly High Conviction Ideas - Newser
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Price Channel Expanding on Zenas BioPharma Inc.’s Chart getLinesFromResByArray error: size == 0 - thegnnews.com
Is Zenas BioPharma Inc. building a consolidation baseQuarterly Profit Review & Long-Term Growth Stock Strategies - Newser
Will earnings trigger a reversal in Zenas BioPharma Inc.2025 Market Overview & Real-Time Volume Analysis - Newser
Has Zenas BioPharma Inc. found a price floorJuly 2025 Price Swings & Weekly Hot Stock Watchlists - Newser
Zenas Biopharma Inc Azioni (ZBIO) Dati Finanziari
Non sono disponibili dati finanziari per Zenas Biopharma Inc (ZBIO). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Zenas Biopharma Inc Azioni (ZBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 18 '24 |
Buy |
17.91 |
10,000 |
179,100 |
1,662,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):